LNTH Q2 2021 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$5B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$101M+53.1% YoY

Gross Profit

$46M45.6% margin

Operating Income

-$27M-26.5% margin

Net Income

-$27M-26.4% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$858M

Total Liabilities

$350M

Stockholders' Equity

$508M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$66M	+53.1%
Gross Profit	$46M	$26M	+78.3%
Operating Income	-$27M	-$6M	-383.0%
Net Income	-$27M	-$7M	-280.2%

Revenue Segments

Product

$94M32%

Total Precision Diagnostics

$90M31%

DEFINITY

$60M20%

Techne Lite

$24M8%

Strategic Partnerships And Other

$8M3%

License and Royalty Revenues

$8M3%

Other Precision Diagnostics

$7M2%

Radiopharmaceutical Oncology

$3M1%